Delcath SystemsDCTH +5.12%70 Days Payable is 74.75 as of Mar. 2026, which is 91% below its 10-year median of 788.71. GuruFocus rates DCTH with a GF Score™ of 70/100 and a GF Value™ of $36.72 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Delcath Systems ranks better than 58.74% on this metric.
The historical rank and industry rank for Delcath Systems's Days Payable or its related term are showing as below:
DCTH'
s Days Payable Range Over the Past 10 Years
Min: 55.99 Med: 788.71 Max: 3108.85
Current: 83.94
During the past 13 years, Delcath Systems's highest Days Payable was 3108.85. The lowest was 55.99. And the median was 788.71.
DCTH's Days Payable is ranked better than 58.74% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs DCTH: 83.94
Delcath Systems's Days Payable
increased
from Mar. 2025 (41.38) to Mar. 2026 (74.75).
It may suggest that Delcath Systemsdelayed paying its suppliers.
Delcath Systems Days Payable Related Terms
Delcath Systems Days Payable Historical Data
* Premium members only.
The historical data trend for Delcath Systems's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Delcath Systems's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Delcath Systems Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Delcath Systems's Days Payable distribution charts can be found below:
* The bar in red indicates where Delcath Systems's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Delcath Systems's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Delcath Systems (DCTH) has a Days Payable of 74.75 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Delcath Systems and its competitors. This is 91% below median its historical median of 788.71. Over the past decade, Delcath Systems' Days Payable has ranged from 55.99 to 3,108.85. According to the industry distribution chart, Delcath Systems ranks #328 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 41.3%.
Is Delcath Systems' Days Payable too high?
Delcath Systems' current Days Payable of 74.75 is 91% below median its 10-year median of 788.71. Over the past 10 years, this metric has ranged from a low of 55.99 to a high of 3,108.85. The Medical Devices & Instruments industry median Days Payable is 67.87. Delcath Systems' value of 74.75 is 10.1% above this industry median. Based on the distribution chart, Delcath Systems ranks #328 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Delcath Systems has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Delcath Systems' Days Payable compare to OFIX and VMD?
According to the Medical Devices & Instruments industry distribution chart, Delcath Systems ranks #328 out of 795 companies for Days Payable. This puts Delcath Systems in the upper half of its industry. The industry median Days Payable is 67.87. Delcath Systems' value of 74.75 is 10.1% above this benchmark. Historically, Delcath Systems' own Days Payable has ranged from 55.99 to 3,108.85 over the past decade. While the company's 10-year median is 788.71 vs. the industry median of 67.87, Delcath Systems has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Delcath Systems's current Days Payable of 74.75 is 10.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Delcath Systems and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Delcath Systems's current Days Payable is 74.75, which is 91% below median its own 10-year median of 788.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Delcath Systems stock overvalued right now?
Based on GuruFocus' analysis, Delcath Systems (DCTH) is currently considered Significantly Undervalued. The stock's GF Value™ is $36.72, compared to a current price of $12.94 — trading 64.8% below its estimated fair value. The current Days Payable is 74.75, which is 91% below median its 10-year median of 788.71 and 10.1% above the Medical Devices & Instruments industry median of 67.87. Delcath Systems' overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Delcath Systems (DCTH), the current Days Payable is 74.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Delcath Systems (DCTH) Overvalued in 2026?
Based on GuruFocus' analysis, Delcath Systems stock appears to be undervalued.
The current stock price of $12.94 is trading 64.8% below its estimated GF Value™ of $36.72.
GuruFocus considers Delcath Systems to be Significantly Undervalued.
Key valuation signals for DCTH:
Days Payable: 74.75 (91% below median its 10-year median of 788.71)
GF Value™: $36.72 vs. price of $12.94 (64.8% below fair value)
Industry Position: 10.1% above the Medical Devices & Instruments median (#328 of 795)
No single metric tells the full story. See the DCTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
70GF Score
Get the complete analysis for DCTH
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DCTH has been successfully added to your 
